Illumina Eyes MDx Revenue in 2009; Working on Genome Analyzer Improvements | GenomeWeb
SAN FRANCISCO (GenomeWeb News) – Illumina anticipates that its BeadXpress and assays that are currently in development will provide the firm’s first proprietary molecular diagnostic revenues in 2009, CEO Jay Flatley told investors today at the JPMorgan Healthcare Conference held here.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.